Trial Profile

An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Somavaratan (Primary)
Indications Somatotropin deficiency
Focus Adverse reactions
Acronyms VISTA
Sponsors Versartis

Most Recent Events

07 Mar 2018 Status changed from active, no longer recruiting to discontinued.
18 Jan 2018 This trial has been discontinued in Poland (end date: 7 Nov 2017).
09 Nov 2017 This trial has been discontinued in Sweden.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com